RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
The relationship between health perception and utility in heart failure patients in a clinical trial
Results from an OVERTURE substudy
Havranek, EP., Simon, TA., L'Italien, G., Smitten, A., Hauber, AB., Chen, R., & Lapuerta, P. (2004). The relationship between health perception and utility in heart failure patients in a clinical trial: Results from an OVERTURE substudy. Journal of Cardiac Failure, 10(4), 339-343. https://doi.org/10.1016/j.cardfail.2003.11.002
Background: Cost-effectiveness analyses should be based on incremental years of life gained adjusted with a health status measure known as a utility. Measuring utilities for all subjects in a large-scale randomized trial, however, would be prohibitively cumbersome. We therefore sought to estimate utilities for all subjects from results obtained in a subset of patients.
Methods and Results: We studied a subset of patients enrolled in a randomized trial of omapatrilat for the treatment of heart failure. Survey instruments (a time trade-off questionnaire, a visual analog scale [VAS] score of overall health perception, and the Duke Activity Status Index [DASI]) were administered to patients by mail and by telephone interviews. There was a significant (P <.0001) relationship between VAS score and utility described by the power function u = 1-(1-v)q, where q = 2.17 (95% CI 1.76 to 2.58). There was a significant positive correlation (r = .17, P <.04) between the DASI and utility, and a significant negative correlation (r = -.26, P <.001) between utility and New York Heart Association functional class.
Conclusion: There is a significant relationship between the relatively easily obtainable health perception score by VAS with the more complex utility by time tradeoff for a subset of patients in a multicenter randomized clinical trial. This relationship may be helpful in examining the cost-effectiveness of new treatments for heart failure.